

Références – Tracleer

1. Robbins IM, et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. *Chest* 1998;114(5):1269-75.
2. Gaine SP, Rubin, LJ. Primary pulmonary hypertension. *Lancet* 1998;352:719-25.
3. Luscher FT, Barton M. Endothelins and endothelin receptor antagonists therapeutic considerations for a novel class of cardiovascular drugs. *Circulation* 2000; 102:2434-2440.
4. Herner SJ, Mauro LS. Epoprostenol in primary pulmonary hypertension. *Ann Pharmacother* 1999;33:340-7.
5. Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996;334:296-301.
6. Monographie du Tracleer, Actelion Pharmaceuticals Ltd., Laval, Québec, 16 novembre 2001.
7. Williamson DJ, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. *Circu* 2000;102:411-8.
8. Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. *Lancet* 2001;358:1119-23.
9. Krum H, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. *N Eng J Med* 1998;338:784-90.
10. McLaughlin VV, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension; *N Eng J Med* 1998; 338(5):273-277.
11. Badesch DB, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. *Ann Intern Med* 200;132:425-34.
12. WHO Classifications of Pulmonary Hypertension: <http://www.who.int/ncd/cvd/pph.html#NomenClass>
13. Contact d'un membre du personnel avec un pharmacien de Calea, 27 mai 2002.
14. Welbanks L, editor. *Compendium of Pharmaceuticals and Specialties, 37th Edition*. Association des pharmaciens du Canada, 2002, Ottawa.
15. L'Office canadien de coordination de l'évaluation des technologies de la santé. Bosentan. *Emerging Drug List* 2002;(21):1-2. <http://www.cchota.ca/newweb/pubapp/pubs.asp>